CL2017000850A1 - Uso de l.reuteri para la recuperación de la disbiosis de microbiota en los primeros años de vida. - Google Patents

Uso de l.reuteri para la recuperación de la disbiosis de microbiota en los primeros años de vida.

Info

Publication number
CL2017000850A1
CL2017000850A1 CL2017000850A CL2017000850A CL2017000850A1 CL 2017000850 A1 CL2017000850 A1 CL 2017000850A1 CL 2017000850 A CL2017000850 A CL 2017000850A CL 2017000850 A CL2017000850 A CL 2017000850A CL 2017000850 A1 CL2017000850 A1 CL 2017000850A1
Authority
CL
Chile
Prior art keywords
microbiota dysbiosis
prevention
functional
disease
treatment
Prior art date
Application number
CL2017000850A
Other languages
English (en)
Inventor
Rodenas Clara Lucia Garcia
Bernard Berger
Bru Catherine Ngom
Melissa Lepage
Tara Neville
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51897072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of CL2017000850A1 publication Critical patent/CL2017000850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pediatric Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A LACTOBACILLUS REUTERI PARA USAR EN IA PREVENCIÓN O EL TRATAMIENTO DE LA DISBIOSIS DE MICROBIOTA, PARTICULARMENTE, MENORES NIVELES DE ACTINOBACTERIA Y MAYORES NIVELES DE PROTEOBACTERIA, EN MAMÍFEROS JÓVENES Y EN LA PREVENCIÓN O EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON ESTA. LA DISBIOSIS DE MICROBIOTA PUEDE HABERSE PROVOCADO POR NUMEROSOS FACTORES, QUE INCLUYEN EL NACIMIENTO POR CESÁREA, EXPOSICIÓN A ANTIBIÓTICOS IN ÚTERO O DESPUÉS DEL NACIMIENTO, O ALIMENTACIÓN PARENTERAL, HOSPITALIZACIÓN, ESTRÉS PSICOLÓGICO O POR DISFUNCIONES GASTROINTESTINALES. LOS TRASTORNOS QUE PUEDEN TRATARSE A PREVENIRSE MEDIANTE LA PREVENCIÓN O EL TRATAMIENTO DE LA DISBIOSIS DE MICROBIOTA INCLUYEN PROPENSIÓN A LA INFECCIÓN, ALERGIA, DIABETES MELLITUS TIPO I, RESISTENCIA A LA INSULINA, DIABETES TIPO 2, ENFERMEDAD CELIACA, ADIPOSIDAD PERIFÉRICA Y CENTRAL, OBESIDAD, ENTEROCOLITIS NECROTIZANTE, ENFERMEDAD INFLAMATORIA DEL INTESTINO, TAL COMO LA ENFERMEDAD DE CROHN YL A COLITIS ULCEROSA, Y TRASTORNOS GASTROINTESTINALES FUNCIONALES, TALES COMA IBS, DIARREA FUNCIONAL, ESTREÑIMIENTO FUNCIONAL, DOLOR ABDOMINAL RECURRENTE Y DISPEPSIA.</p>
CL2017000850A 2014-10-29 2017-04-07 Uso de l.reuteri para la recuperación de la disbiosis de microbiota en los primeros años de vida. CL2017000850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14190941 2014-10-29

Publications (1)

Publication Number Publication Date
CL2017000850A1 true CL2017000850A1 (es) 2017-11-03

Family

ID=51897072

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000850A CL2017000850A1 (es) 2014-10-29 2017-04-07 Uso de l.reuteri para la recuperación de la disbiosis de microbiota en los primeros años de vida.

Country Status (17)

Country Link
US (2) US11369646B2 (es)
EP (1) EP3212208B1 (es)
KR (2) KR20170072879A (es)
CN (2) CN106794207A (es)
AU (1) AU2015340605B2 (es)
BR (1) BR112017005612A2 (es)
CA (1) CA2960337C (es)
CL (1) CL2017000850A1 (es)
DK (1) DK3212208T3 (es)
ES (1) ES2870425T3 (es)
MX (1) MX2017005497A (es)
MY (1) MY186733A (es)
PH (1) PH12017500334B1 (es)
PL (1) PL3212208T3 (es)
RU (1) RU2723687C2 (es)
WO (1) WO2016066763A1 (es)
ZA (1) ZA201703635B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) * 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
EP3536168A3 (en) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
JP2018517775A (ja) * 2015-06-16 2018-07-05 マードック チルドレンズ リサーチ インスティチュート クローン病を治療する方法
EP3322408B1 (en) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
WO2017182796A1 (en) * 2016-04-19 2017-10-26 Genome Research Limited Bacteriotherapy
CA3029631A1 (en) 2016-07-01 2018-01-04 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system
WO2018046311A1 (en) * 2016-09-07 2018-03-15 Nestec S.A. Nutritional compositions for infants and/or young children comprising oligosaccharides
EP4159224A1 (en) * 2017-06-30 2023-04-05 N.V. Nutricia Synbiotic composition for preventing chronic inflammation
EP3672600A4 (en) 2017-08-21 2021-05-19 Glycom A/S SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS
US11452736B2 (en) * 2017-11-30 2022-09-27 Glycom A/S Mixture of HMOs for treating wheat sensitivity
ES3039971T3 (en) 2017-12-08 2025-10-28 Chr Hansen Hmo Gmbh Spray-dried 3-fucosyllactose
PL3494805T3 (pl) 2017-12-08 2025-10-06 Chr. Hansen HMO GmbH Suszone rozpyłowo tetrasacharydy
GB2573538B (en) * 2018-05-09 2023-01-04 Mjn Us Holdings Llc Pediatric nutritional compositions and methods for infants delivered by C-section
WO2020028871A1 (en) * 2018-08-03 2020-02-06 Research Institute At Nationwide Children's Hospital Prenatal probiotic formulations
WO2020033440A1 (en) * 2018-08-10 2020-02-13 The Regents Of The University Of California Methods and compositions for treating and preventing inflammatory diseases
EP3870154A4 (en) * 2018-10-22 2022-07-27 Research Institute at Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-INDUCED PATHOLOGIES USING PROBIOTICS IN BIOFILM STATE
MX2021007599A (es) * 2018-12-19 2021-10-13 Healthy Cow Corp Composiciones probióticas listas para utilizar y usos de las mismas.
FR3093427B1 (fr) * 2019-03-05 2021-03-05 Mativa Tech Composition pour son utilisation dans la prévention et/ou le traitement de la dysbiose
KR102978329B1 (ko) 2019-06-03 2026-06-17 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
KR102621775B1 (ko) * 2019-06-11 2024-01-08 씨제이바이오사이언스 주식회사 영유아의 장내 미생물 불균형도를 탐지하는 방법
CN110591945A (zh) * 2019-09-06 2019-12-20 吉林大学 一株用于预防溃疡性结肠炎的优良罗伊氏乳杆菌
KR102529206B1 (ko) * 2019-12-20 2023-05-08 충북대학교 산학협력단 신규한 락토바실러스 루테리 ｄｂ２ 균주 및 이의 용도
CN111254090B (zh) * 2019-12-30 2021-11-05 杭州娃哈哈科技有限公司 一株具有减肥功能的罗伊氏乳杆菌及其应用
CN111265553B (zh) * 2020-01-23 2021-06-22 湖南菲勒生物技术有限公司 一株母乳来源罗伊氏乳杆菌调节母婴免疫功能的应用
EP4056053A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Pre-conditioning of l. reuteri
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
CN113073066B (zh) 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
FR3126869B1 (fr) 2021-09-16 2026-06-19 Gozen K K Japan Composition pharmaceutique comprenant des métabolites issus de la bactérie Bacillus subtilis Gozen GZN-08 isolée de Camellia sinensis et modulant la réponse immunitaire.
CN114107088B (zh) * 2021-10-20 2023-07-21 山西大学 一种罗伊氏乳杆菌lrsy523及其应用
CN113943687B (zh) * 2021-12-21 2022-02-22 山东中科嘉亿生物工程有限公司 一种改善溃疡性结肠炎的罗伊氏乳杆菌jylb-291及其应用
CN114990004B (zh) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
US20260137737A1 (en) * 2022-10-13 2026-05-21 Baylor College Of Medicine Secretin inducing bacteria
US20260144831A1 (en) * 2022-11-30 2026-05-28 Board Of Regents, The University Of Texas System Prenatal probiotic cocktail to reduce risk for neurodevelopmental disorder-associated maladaptive behavioral symptoms in children
KR20240150943A (ko) 2023-04-10 2024-10-17 (주)인트젠 영유아용 유산균 프로바이오틱스 조성물
KR102752058B1 (ko) 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물
WO2025206977A1 (ru) * 2024-03-29 2025-10-02 Александр Владимирович Синица Штамм бактерий lactobacillus reuteri, подавляющий активность helicobacter pylori
CN117982544B (zh) * 2024-04-03 2024-07-05 哈尔滨葵花药业有限公司 一株罗伊氏粘液乳杆菌Glory LR15在调节肥胖型哮喘产品中的应用
CN120192865A (zh) * 2024-11-07 2025-06-24 河北农业大学 一种罗伊氏粘液乳杆菌mry6及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP2127661A1 (en) * 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
CN102065872A (zh) * 2008-05-27 2011-05-18 雀巢产品技术援助有限公司 改善肠微生物群的益生菌
EP2147678A1 (en) * 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
EP2609813A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
MY187609A (en) * 2012-12-18 2021-10-04 Abbott Lab Human milk oligosaccharides to ameliorate symptoms of stress
WO2015177246A2 (en) * 2014-05-20 2015-11-26 Biogaia Ab Neonatal microbiome supplementation

Also Published As

Publication number Publication date
MX2017005497A (es) 2017-09-15
AU2015340605A1 (en) 2017-03-16
EP3212208B1 (en) 2021-03-03
KR20220163503A (ko) 2022-12-09
BR112017005612A2 (pt) 2017-12-12
RU2017118358A3 (es) 2019-03-05
MY186733A (en) 2021-08-15
AU2015340605B2 (en) 2021-06-24
PL3212208T3 (pl) 2021-09-06
DK3212208T3 (da) 2021-05-17
US11701397B2 (en) 2023-07-18
US20180280454A1 (en) 2018-10-04
ZA201703635B (en) 2019-06-26
KR102606971B1 (ko) 2023-11-30
ES2870425T3 (es) 2021-10-27
PH12017500334A1 (en) 2017-07-17
RU2723687C2 (ru) 2020-06-17
WO2016066763A1 (en) 2016-05-06
EP3212208A1 (en) 2017-09-06
RU2017118358A (ru) 2018-11-29
CA2960337C (en) 2022-04-05
CA2960337A1 (en) 2016-05-06
CN106794207A (zh) 2017-05-31
KR20170072879A (ko) 2017-06-27
CN116650541A (zh) 2023-08-29
PH12017500334B1 (en) 2023-07-05
US11369646B2 (en) 2022-06-28
US20220331380A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
BR112017005612A2 (pt) uso de l. reuteri para recuperação da disbiose da microbiota na fase inicial da vida
CL2017001438A1 (es) Antagonistas de miostatina o activina para el tratamiento de sarcopenia
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
MX421305B (es) Probioticos para su uso en el tratamiento de diverticulosis y enfermedad diverticular.
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2015000300A1 (es) Compuestos derivados de pirroles y pirazoles sustituidos, moduladores del receptor nuclear huerfano ror gamma; composicion farmaceutica; uso en el tratamiento o profilaxis de enfermedades del sistema inmunitario tales como artritis reumatoide, lupus eritematoso, esclerosis multiple, epoc, entre otras.
MX2015000990A (es) Analogos del glucagon.
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
MX2018012605A (es) Administracion de vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el tratamiento de la distrofia muscular.
MX2018011392A (es) Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal.
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
DOP2017000094A (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
CO2017008870A2 (es) Análogos de amilina
MX2015004844A (es) Firmas geneticas de trastornos inflamatorios que se relacionan con el higado.
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.
BR112016023752A2 (pt) utilização de lactobacillus rhamnosus para promover a recuperação da diversidade da microbiota intestinal após disbiose
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
MX2017001566A (es) Terapias antibioticas peptidicas derivadas del bufalo de agua.
CL2018002515A1 (es) Liraglutida en afecciones cardiovasculares.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica